PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Loncar China BioPharma ETF (CHNA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

ETF Info

ISINUS26922A3703
CUSIP26922A370
IssuerExchange Traded Concepts
Inception DateAug 14, 2018
RegionEmerging Asia Pacific (China)
CategoryHealth & Biotech Equities, China Equities
Index TrackedLoncar China BioPharma Index
Asset ClassEquity

Asset Class Size

Multi-Cap

Asset Class Style

Blend

Expense Ratio

The Loncar China BioPharma ETF has a high expense ratio of 0.79%, indicating higher-than-average management fees.


0.50%1.00%1.50%2.00%0.79%

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Loncar China BioPharma ETF

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Loncar China BioPharma ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%Oct 22Oct 29Nov 05Nov 12Nov 19Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31
-99.42%
9.04%
CHNA (Loncar China BioPharma ETF)
Benchmark (^GSPC)

S&P 500

Returns By Period


PeriodReturnBenchmark
Year-To-DateN/A5.29%
1 monthN/A-2.47%
6 monthsN/A16.40%
1 yearN/A20.88%
5 years (annualized)N/A11.60%
10 years (annualized)N/A10.43%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-4.83%-99.46%-3.95%-13.70%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Loncar China BioPharma ETF (CHNA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


CHNA
Sharpe ratio
No data
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.79, compared to the broader market0.002.004.001.79
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.61, compared to the broader market-2.000.002.004.006.008.002.61
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market1.001.502.002.501.31
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.002.004.006.008.0010.0012.001.36
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0020.0040.0060.0080.007.21

Sharpe Ratio


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00Oct 22Oct 29Nov 05Nov 12Nov 19Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31
-0.72
1.72
CHNA (Loncar China BioPharma ETF)
Benchmark (^GSPC)

Dividends

Dividend History

Loncar China BioPharma ETF granted a 60.12% dividend yield in the last twelve months. The annual payout for that period amounted to $0.05 per share.


PeriodTTM20232022202120202019
Dividend$0.05$0.05$0.00$3.03$0.15$0.04

Dividend yield

60.12%77.30%0.00%11.33%0.47%0.16%

Monthly Dividends

The table displays the monthly dividend distributions for Loncar China BioPharma ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDec
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.05$0.00$0.00
2022$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2021$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$3.03
2020$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.15
2019$0.04

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Oct 22Oct 29Nov 05Nov 12Nov 19Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31
-99.81%
-1.91%
CHNA (Loncar China BioPharma ETF)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Loncar China BioPharma ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Loncar China BioPharma ETF was 99.88%, occurring on Dec 8, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.88%Jun 29, 2021580Dec 8, 2023
-30.37%Aug 28, 201879Jan 3, 2019255Jan 16, 2020334
-22.92%Feb 19, 202019Mar 16, 202043May 15, 202062
-16.62%Feb 18, 202113Mar 8, 202135Apr 27, 202148
-13.47%Aug 6, 202062Nov 2, 202046Jan 8, 2021108

Volatility

Volatility Chart

The current Loncar China BioPharma ETF volatility is 492.38%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%100.00%200.00%300.00%400.00%500.00%Oct 22Oct 29Nov 05Nov 12Nov 19Nov 26Dec 03Dec 10Dec 17Dec 24Dec 31
492.38%
2.95%
CHNA (Loncar China BioPharma ETF)
Benchmark (^GSPC)